CDNF Safe in Advanced Parkinson’s, Trial Results Show
Treatment with cerebral dopamine neurotrophic factor (CDNF), developed by Herantis Pharma, was safe and well-tolerated among patients with advanced-stage Parkinson’s disease, according to topline results from a Phase1/2 clinical trial. The therapy also showed promise in measures of dopaminergic function in some patients. CDNF is based…